Introduction
============

Cellular diversity is a principal morphologic and functional property of the brain. It includes the existence of different classes of neuronal, astroglial, microglial, and oligodendroglial cells, and also several supporting vascular and meningeal membranes cells. The neurons constitute a relatively small but highly heterogenous, and not evenly distributed, fraction of the whole brain cell population ([@B55]). Their principal function neurotransmission includes synthesis, vesicular accumulation, and quantal release of diverse neurotransmitters and regulatory compounds. The former, when released in quantal mode from depolarized axonal terminals, may exert either activatory or inhibitory effects on postsynaptic parts of recipient neurons. Continuous generation of action potentials and restoration of resting membrane potentials with a 5--50 Hz frequency, requires high rates of energy production. These two neuronal parameters may be traced *in vivo* by electroencephalography and CT-PET-MRI functional imaging ([@B63]). Three dimensional mapping and dynamic studies of regional^18^F-deoxyglucose uptake, or changes in phosphocreatine, ATP, *N-*acetyl-[L]{.smallcaps}-aspartate (NAA) or lactate levels may provide a precise picture of energy metabolism in each selected anatomical structure of the brain. They also provide an accurate localization and analysis of metabolic disturbances in diverse brain pathologies ([@B74]; [@B71]; [@B210]). Several reports indicate that shifts in cellular compartmentation and rates of metabolism of direct energy precursors such as pyruvate/lactate and its conversion to acetyl-CoA by PDHC may take part in the adaptative processes during brain maturation, aging, and diverse neuropathophysiological conditions ([@B53]; [@B66]). Hence, acetyl-CoA as an immediate substrate for TCA and diverse key acetylation reactions should be considered as one of the key regulatory signals in these conditions ([@B166], [@B171]; [@B130]; [@B123]).

Acetyl-CoA Precursors in the Brain
==================================

Glucose and Derived Metabolites as a Principal Source of Acetyl-CoA and Energy in the Brain
-------------------------------------------------------------------------------------------

Neurons contribute to 50--80% of overall energy balance of the whole brain using glucose oxidative metabolism as a principal energy source. Its adequate provision is assured by the presence of the high capacity medium affinity GLUT1 transporter (Km ∼ 8.0 mM) on the blood brain barrier and the high affinity GLUT3 transporter (Km ∼ 2.8 mM) on neuronal plasma membranes, respectively ([@B154]). They may secure an adequate glucose supply even at serious hypoglycemic conditions of 2 mM range. In addition, the expression of GLUT1 transporter is inversely regulated by glycemia adapting the brain to chronic hyper or hypoglycemic conditions. Such homeostatic mechanisms stabilize glucose availability in brain extracellular compartments. The high energy demand in neurons results from their neurotransmitter functions linked with continuous depolarization/repolarization cycles of 5--50 Hz frequency. The maintenance of this basal neuronal function requires marked energy expenses for the restoration of membrane potential and preservation of the stable neurotransmitter pool in synaptic vesicles. Therefore, neurons are more susceptible than glial cells to diverse range pathologic inputs that limit the supply of oxygen and/or glucose and lactate as principal energy substrates ([@B166], [@B171]).

On the other hand, glial cells -- that outnumber neurons depending on the region by 10 to 1 -- produce only ca. 30--40% of the overall brain energy pool, utilizing a 50% fraction of supplied glucose ([@B69]; [@B55]). This divergence is caused by the fact that glial cells, mainly astrocytes, are net producers of lactate due to the relative prevalence of glycolysis over oxidative metabolism. The lactate released from the glial cells is taken up by neurons through MCT2 monocarboxylate transporters, of high affinity to lactate and pyruvate with Km values equal to 0.5 and 0.1 mM, respectively ([@B127]). Reuptake of lactate by astroglia is prevented due to the presence of low affinity MCT4 transporters of Km about 25 mM. Thereby, lactate may be complementary to the glucose source of intraneuronal pyruvate, which in mitochondria is metabolized by PDHC, yielding acetyl-CoA. The latter is an energy precursor directly feeding the TCA cycle through citrate synthase step. In fact cultured neuronal cells grow and function well with pyruvate/lactate as the only energy substrates in the medium ([@B203]). On the other hand, there are indications that *in vivo* both neurons and astroglia produce an excess of lactate, making the net contribution of extracellular lactate to the neuronal energy metabolism non-significant ([@B96]). Astroglial cells also synthesize and release large amounts of [L]{.smallcaps}-glutamine, which is taken up by adjacent neurons. In glutamatergic and GABA-ergic neurons it is converted by phosphate activated glutaminase (EC 3.5.1.2) and glutamate decarboxylase (EC 4.1.1.15) to neurotransmitters: glutamate and γ-aminobutyrate (GABA), respectively.

In astrocytes, a fraction of glutamate, after conversion to α-ketoglutarate by glutamate dehydrogenase (EC 1.4.1.2)/aspartate aminotransferase (EC 2.6.1.1) reactions, may enter the TCA cycle at the KDHC step ([@B194]). In neurons, this pathway is much less active. Therefore, in neurons the metabolic flux of pyruvate through PDHC remains a key factor that determines the availability of acetyl-CoA for energy production in mitochondrial compartment and maintenance of their viability ([@B178], [@B166]). In accordance with this, the activities of PDHC in the brain homogenates and isolated mitochondria were found to be 4 -- 10 times higher than in respective fractions of non-excitable tissues ([@B161]; [@B174]; [@B184]; [@B8]). Also, rates of glucose uptake, glycolysis and pyruvate utilization in brain neurons are significantly higher than in astroglial, microglial, or oligodendroglial cells ([@B54]; [@B96]; [@B73]). These findings are compatible with lower rates of overall oxidative metabolism in the glial than in the neuronal compartment ([@B182]). Therefore, physiologic and pathologic alterations of overall brain energy metabolism, observed in CT-PET-MRI as images of phosphocreatine, or NAA, reflect those taking place mainly in the neuronal compartments ([@B74]).

Beta-Hydroxybutyrate/Acetoacetate and Brain Acetyl-CoA
------------------------------------------------------

Brain cells are also capable utilizing β-hydroxybutyrate/ acetoacetate (β-HB, AcAc) as a complementary source of acetyl-CoA both for energy production in mitochondria and for cytoplasmic synthetic pathways. Under physiologic non-fasting conditions their plasma concentrations are below 0.05 mM, which precludes their effective transport by MCT2 transporter, as its Kms for these metabolites are about 1 mM ([@B127]). Therefore, at similar concentrations the uptake and rate of β-HB metabolism are 5 times slower than those of pyruvate. However, in a starvation or diabetic ketoacidosis brain, the levels of β-HB may rise up to 5 and higher millimolar concentrations. In such conditions β-HB may enter the brain cell mitochondria, being effectively metabolized to acetyl-CoA through β-hydroxybutyrate dehydrogenase (HBDH, EC 1.1.1.30), 3-oxoacid CoA-transferase (EC 2.8.3.5.), and acetoacetyl-CoA thiolase (EC 2.3.1.9) pathways ([@B19]; [@B28]). In brain nerve terminals, β-HB in concentrations of 2.5--20.0 mM could supply up to a 30% pool of acetyl-CoA required for energy production and diverse synthetic pathways, including ACh synthesis ([@B179], [@B177]). In such conditions, β-HB slightly reduced pyruvate utilization due to competition for MCT2 transporter ([@B179]; [@B127]). However, it did not affect glucose oxidation ([@B102]). Therefore, under ketonemic conditions β-HB may support glucose in the maintenance of the proper level of acetyl-CoA in the brain ([@B179], [@B177]; [@B154]).

In fact β-HB markedly increased the level of acetyl-CoA in the mitochondrial compartment of brain nerve terminals (**Figure [1B](#F1){ref-type="fig"}**) ([@B177]). Synaptosomes from the brains of diabetic-ketonemic rats displayed higher levels of acetyl-CoA and rates of ACh synthesis ([@B179], [@B177]). β-HB may also prevent death of glucose deprived cultured primary cortical neurons, in energy independent mode through acetylation-induced degradation of LC3-II/p62 proteins in activated autophagosomes ([@B21]). In high concentration β-HB also increased oxygen consumption, ATP levels, histone acetylation, and BDNF expression in cultured primary neurons from mice brain, yielding an increase of their resistance to oxidative stress ([@B98]). Recent studies demonstrated that dietary feeding of 3xTg mice with β-HB increased the level of acetyl-CoA, accompanied by increases in NAA, citrate, and other TCA intermediates in hippocampus along with an improvement in behavioral tests ([@B121]).

![Alterations of acetyl-CoA levels in forebrain cellular compartments in different experimental models of neurotoxicity and neurodegeneration. **(A)** Effects of variations in pyruvate uptake on acetyl-CoA level in whole brain (predominately glial) mitochondria treated with different cytotoxic and cytoprotective compounds. **(B)** Effects of alterations in pyruvate uptake by isolated brain synaptosomes on acetyl-CoA level in their mitochondria. **(C)** Effects of Zn overload of SN56 non-differentiated (blue) and differentiated (red) cholinergic neuroblastoma cells (blue and red numbers indicate intracellular Zn in nmol/mg protein) on acetyl-CoA level in whole cells and cell's mitochondria and their *N*-acetylaspartate content. **(D)** Correlations between cytoplasmic and mitochondrial acetyl-CoA levels in synaptosomes treated with cytotoxic/cytoprotective agents increasing (green plot) or decreasing/not affecting mitochondrial membrane permeability (blue plot). The gray dotted line corresponds to theoretical stoichiometric compartmentalization of acetyl-CoA. **(E)** Effect of alterations in synaptoplasmic acetyl-CoA level on maximal Ca**^++^**/K^+^ depolarization-evoked acetylcholine release/synthesis in synaptosomes treated with different cytotoxic and cytoprotective compounds. **(F)** Effect of alterations in synaptoplasmic acetyl-CoA level on Ca-dependent (quantal) acetylcholine release by synaptosomes treated with different cytotoxic and cytoprotective compounds. Al, aluminum 0.25 mmol/L; BrP, 3-bromopyruvate 0.25 mmol/L; Ca, Calcium 0.01 and 0.1 with mitochondria, Ca 1.0 mmol/L with synaptosomes; DCA, dichoroacetate 0.05 mmol/L; HB, β-hydroxybutyrate 20 mmol/L; HC, (--) hydroxycitrate 1.0 mmol/L; PT, pyrythiamin-thiamin deficient synaptosomes; SNP, sodium nitroprusside 0.2 and 1.0 mmol/L; Tg2576, transgenic AD mice; VE, verapamil 0.1 mmol/L. Data were recalculated to relative values from original data: [@B9], [@B170], [@B167]), [@B183], [@B11], [@B8]), [@B65], [@B213].](fncel-12-00169-g001){#F1}

PET-MRI studies revealed that, in contrast to glucose, AcAc metabolism is not altered in the brains of AD patients ([@B34]; [@B24]). Thus, the apparent neuroprotective effects of this ketoacid could result from the supply of acetyl-CoA by pathway bypassing glycolysis and PDHC, which are impaired in AD and other neurodegenerative diseases ([@B178], [@B177], [@B166]; [@B18]; [@B205]; [@B65]; [@B21]; [@B71]; [@B121]). The ketone-evoked support of acetyl-CoA/energy metabolism may explain their protective effects against amyloid toxicity in brains of PDGFB-APPSwInd AD mice ([@B206]). These findings indicate that intermittent metabolic glucose to β-HB switching, linked with fasting-feeding cycles, may promote neuroplasticity and resistance to neurodegeneration ([@B101]). This would be compatible with the thesis that caloric restriction -- known to lengthen the lifespan of several species -- may be mediated through β-HB increasing supplementation of NAPH, and expression of antioxidant enzymes ([@B192]). Clinical studies have revealed that caloric restriction, which induces ketonemia, was accompanied by slight improvements of cognitive functions in elderly people with mild cognitive impairment ([@B79]). Such mechanism may also contribute to the ability of β-HB to calm neuronal spiking in epileptic brains, and decrease the incidence of subclinical epileptiform activity in AD patients ([@B193]).

In glial cells, activities of HBDH and acetoacetyl-CoA thiolase were found to be two--threefold higher than in neurons ([@B28]). Therefore, in ketonemic conditions these ketoacids may became a significant precursor of intramitochondrial acetyl-CoA in non-neuronal cellular compartments of the brain. These data indicate that irrespective of origin, acetyl-CoA is a central point of energy metabolism in cell mitochondria and a primary precursor for multiple synthetic and signaling pathways in various extramitochondrial compartments ([@B166], [@B171]).

The level of acetyl-CoA in every cell type, including neurons and neuroglia, is resultant of rates of its synthesis and utilization within mitochondria and outward transport for consumption in a broad range of synthetic pathways taking place in extramitochondrial compartments ([@B178], [@B166], [@B171]; [@B77]; [@B130]; [@B36]).

Acetate and Brain Acetyl-CoA
----------------------------

Acetate has to be reactivated by acetyl-CoA synthase (ACS, EC 6.2.1.1.). Oligodendroglia expresses acetyl-CoA synthases 1 and 2 that are located in cytoplasmic and mitochondrial compartments. They may resynthesize acetyl-CoA, supplying it directly for myelin lipids synthesis/protein acetylations, and energy production, respectively ([@B134]; [@B176]; [@B107]). Low activities of ACS in nerve terminals and relatively high ones in whole brain mitochondrial fractions point to neuroglia as a principal acetate utilizing compartment of the brain ([@B161]; [@B176]; [@B107]). However, the rate of acetate uptake was found to be independent of astroglia activity. It would suggest no direct modulating contribution of acetate to the energy metabolism of astroglial cells ([@B144]). On the other hand, substantial amounts of endogenous acetate may be formed by hydrolysis of acetyl-CoA, which is generated by PDHC from pyruvate derived from glucose or lactate ([@B91]; [@B133]). Such a thesis is also supported by the fact that over 80% of brain acetyl-CoA hydrolase (EC 3.1.2.1) activity is located in whole brain mitochondria and synaptosomal mitochondria fractions ([@B173], [@B176]). In fact, whole brain mitochondria utilizing pyruvate without provision of oxaloacetate, released significant amounts of acetate ([@B91]). On the other hand, low *V*~max~ and high acetyl-CoA Km of cytoplasmic acetyl-CoA hydrolase may suggest very slow metabolic flux through this catabolic pathway ([@B132]; [@B59]; [@B158]). Nevertheless, intramitochondrially generated acetate, after being transferred to the cytoplasm, could be used by chromatin-bound ACS2 for direct acetylations of nuclear histones, yielding alterations in gene expression in brain neurons. Through such a mechanism the acetate could regulate memory consolidation in the hippocampus ([@B103]). These findings also suggest that the regulatory effects of acetate on cell metabolism occur rather *via* altering levels of acetylation of regulatory proteins than by direct influx into energy generating pathways ([@B144]).

Citrate and Brain Acetyl-CoA
----------------------------

One should stress that in brain mitochondria the rate of acetyl-CoA utilization for citrate synthesis is about two orders of magnitude higher than the rate of its hydrolysis when comparing *V*~max~ values of citrate synthase and acetyl-CoA hydrolase, respectively (**Table [1](#T1){ref-type="table"}**) ([@B202]; [@B158]). Also, isolated whole brain mitochondria or synaptosomes utilizing pyruvate with malate, accumulated several times greater amounts of citrate than those of acetate ([@B91]). Citrate is released from mitochondria to the cytoplasm by the citrate-malate antiporter mechanism, where it is converted back to acetyl-CoA through ATP-citrate lyase reaction (ACL, EC 2.3.3.8.) ([@B156]; [@B1]; [@B168], [@B178]; [@B48]). The (-)hydroxycitrate (HC) in 1 mmol/L concentration was found to be specific, competitive to citrate inhibitor of ACL ([@B180]). At 0.5 mmol/L citrate concentration, comparable with its levels in the brain, being in range of 0.2--0.4 mmol/L, HC with Ki of 3.8 μmol/L, brought about complete inhibition of brain ACL activity, without affecting other enzymes involved in acetyl-CoA and energy metabolism ([@B180]; [@B22]; [@B121]). Therefore, HC was used as a selective tool for investigating the significance of the ACL pathway in maintenance of the proper level of cytoplasmic acetyl-CoA and its contribution to different extramitochondrial synthetic pathways in the brain ([@B119]; [@B180], [@B168], [@B169], [@B178], [@B166]; [@B137], [@B138]; [@B31]).

###### 

The acetyl-CoA Km values for acetyl-CoA consuming enzymes in different cellular compartments.

  --------------------------------------------------------------------------------------------------------------------------------------------------------
  Enzyme                                                 Tissue/cells                  Compartment             Km (μmol/L)   Reference
  ------------------------------------------------------ ----------------------------- ----------------------- ------------- -----------------------------
  Citrate synthase                                       Rat brain                     Mitochondria            4.8           [@B100]

  Carnitine acetyltransferase                            Human liver                   Mitochondria            21.3          [@B14]

  Aspartate acetyltransferase                            Rat brain                     Mitochondria            58            [@B92]

  Acetyl-CoA hydrolase                                   Rat liver\                    Cytoplasm\              150\          [@B158]\
                                                         Rat liver\                    Cytoplasm\              60\           [@B132]\
                                                         Rat liver                     Peroxisomes             400           [@B59]

  Choline acetyltransferase                              Rat brain\                    Cytoplasm\              38\           [@B143]\
                                                         Human brain\                  Cytoplasm\              32--200\      [@B76]\
                                                         regions\                      Highly purified\        46.5\         [@B145]
                                                         Rat brain\                    Highly purified         16.5          
                                                         Bovine brain                                                        

  Sphingosine kinase 1(COX2 acetyltransferase)           Mouse brain neurons           Cytoplasm               58.2          [@B84]

  Acetyl-glutamate synthetase                            Rat liver                     Mitochondria            600           [@B32]

  Acetyl-CoA carboxylase                                 Rat muscles\                  Cytoplasm               31.7 ± 1.5\   [@B186]
                                                         Rat adipose\                                          21.5 ± 1.0    
                                                         tissue                                                              

  Fatty acid synthase                                    Rat liver (purified)          Cytoplasm               4.4           [@B135]

  Acetyl-CoA acetyltransferase                           Rat liver                     Peroxisomes\            \<200\        [@B59]\
                                                                                       Mitochondria            237           [@B104]

  3-hydroxy-3-methyl glutaryl coenzyme A synthase        Ox liver (purified)           Cytoplasm               158           [@B88]

  ER membrane acetyl-CoA transporter (AT-1)              CHO Cell culture              Endoplasmic reticulum   14            [@B31]

  Lysine acetyltransferase BACE1                         CHO Cell culture              Endoplasmic reticulum   14            Puglielli (personal report)

  Lysine acetyltransferase 8 KAT8 (histone 4)            Recombinant enzyme            Nucleus                 1.1-4.8       [@B198]

  Histone acetyltransferase Tip 60                       HeLa cell nuclear extract     Nucleus                 2.0           [@B42]

  Histone acetyltransferase p300/CPB associated factor   Recombinant from Sf21 cells   Nucleus                 0.3           [@B3]
  --------------------------------------------------------------------------------------------------------------------------------------------------------

In depolarized nerve terminals isolated from the rat forebrain, utilizing pyruvate or glucose, 1 mmol/L HC caused a ca. 30% decrease of cytoplasmic and no alterations in intramitochondrial levels of acetyl-CoA, accompanied by respective increase of citrate accumulation and a decrease of ACh synthesis ([@B180], [@B168], [@B170]). A comparable, although wide range of 20--50% suppressive effects, were observed in brain slices with higher 2.5--5.0 mmol/L concentrations of HC ([@B157]; [@B138]; [@B45]). It should be stressed that at such high concentrations, HC could exert weaker unspecific inhibitory effects on other enzymes of the citrate metabolism, as well as on PDHC and phosphofructokinase ([@B29]; [@B168]). In addition, they represent averaged data from multiple subcellular neuronal and glial compartments of acetyl-CoA metabolism, which might respond differentially to the same experimental conditions ([@B138]; [@B73]; [@B213]). These findings indicate that metabolic flux through ACL step influences both acetyl-CoA availability in cytoplasmic compartment and citrate homeostasis in neuronal cells ([@B180], [@B168], [@B170]; [@B138]).

### ATP-Citrate Lyase Pathway and Cholinergic Metabolism

The rates of various extramitochondrial synthetic pathways may depend directly on the acetyl-CoA level, considering Km values of respective enzymes to this substrate as a putative regulatory factor (**Tables [1](#T1){ref-type="table"}, [2](#T2){ref-type="table"}**). Hence, in brain synaptosomes and slices, HC brought about inhibition of ACh synthesis/release, roughly proportional to HC-evoked decreases of acetyl-CoA levels ([@B137], [@B138]; [@B168], [@B170]). In brains of suckling animals, HC caused non-proportionally greater, over 60% inhibition, of non-saponifiable lipids and fatty acid synthesis ([@B119]). These data indicate a significant role of the ACL pathway in regulation of both ACh and lipid synthesis in brain cell cytoplasmic compartments. However, differential inhibition of both synthetic pathways by HC suggests the existence of separate cytoplasmic sub-compartments in neuronal and glial cells, being lesser and more dependent on the supply of acetyl-CoA through the ACL pathway, respectively. Also HC-evoked inhibition of ACh synthesis varied regionally, being low (17%) in the hippocampus, intermediate (30%) in the caudate nucleus, and high (55%) in the septum ([@B138]; [@B45]). These data demonstrate that the fractional contribution of the ACL pathway providing acetyl-CoA for ACh synthesis may be significantly different in various regional subpopulations of brain cholinergic neurons ([@B157]; [@B138]; [@B45]).

###### 

Estimated molar concentrations of acetyl-CoA in different compartments of the brain and clonal cells of brain origin.

  Experimental model                            Calculated concentration (μmol/L cell water)   Reference
  --------------------------------------------- ---------------------------------------------- ---------------------------------
  Rat cerebrum                                  7.0 ± 0.2                                      [@B148]
  Rat whole brain cortex                        6.6 ± 0.3                                      [@B52]
  Rat whole brain cortex                        8.1 ± 0.5                                      [@B152]
  Rat whole thalamus                            11.8 ± 0.8                                     
  Rat whole hippocampus                         9.2 ± 0.5                                      
  Rat whole striatum                            9.0 ± 0.5                                      
  Rat whole cerebellum                          7.8 ± 0.5                                      
  Nucleus caudatus (slices)                     5.3 ± 0.1                                      [@B137]
  Rat whole brain newborn                       4.5 ± 0.2                                      [@B105]
  60 days old                                   2.5 ± 0.1                                      
  Rat whole forebrain                           8.5 ± 0.4                                      [@B163]
  Rat whole forebrain synaptosomes              7.7 ± 0.3                                      [@B9]; [@B170],[@B179], [@B177]
  Rat synaptosomal mitochondria                 7.5 ± 0.3                                      [@B11];
  Rat synaptosomal cytoplasm                    6.3 ± 0.2                                      [@B184];
  Rat Whole forebrain mitochondria              17.6 ± 0.5                                     [@B65]
  Rat whole brain                               3.4 ± 1.3                                      [@B120]
  Rat whole frontal cortex                                                                     [@B212]
  Rat ethanol susceptible                       128 ± 9                                        
  Rat ethanol resistant                         99 ± 5                                         
  Mice forebrain synaptosomes                   9.5 ± 0.7                                      [@B8]
  Mice forebrain synaptosomal mitochondria      14.1 ± 1.6                                     
  Mice forebrain synaptosomal cytoplasm         13.5 ± 0.5                                     
  Mice forebrain whole forebrain mitochondria   15.7 ± 0.4                                     
  Mice neonatal brain crude mitochondria        28.5 ± 2.7                                     [@B160]
  Rat whole brain                               4.0 ± 1.5                                      [@B153]
  Clonal cell lines                                                                            
  SN56 cholinergic neuroblastoma                9.6 ± 0.2                                      [@B175], [@B165];
  Mitochondria                                  10.9 ± 0.4                                     [@B141];
  Cytoplasm                                     7.2 ± 0.2                                      [@B13];
  SHY5Y dopaminergic neuroblastoma              11.6 ± 0.9                                     [@B73];
  N9 microglial cells                           15.9 ± 0.8                                     [@B213]
  C6 astroglial cells                           4.5 ± 0.4                                      

Molar concentrations of acetyl-CoA in whole brain were recalculated from original data expressed as nmol/g tissue or pmol/mg protein assuming water and protein contents in whole brain being equal to 77% and 107 mg/g of tissue, respectively (

Szutowicz et al., 1982

;

Kozler et al., 2013

). In subcellular fractions recalculations of pmol/mg protein data to molar concentrations were done assuming protein concentrations 150 and 350 mg/ml of water for cytoplasmic and mitochondrial fractions, respectively, (

Nolin et al., 2016

).

This specific demand for citrate as a precursor of cytoplasmic acetyl-CoA for ACh synthesis may be met due to preferential localization of ACL in cholinergic neurons ([@B161]; [@B173], [@B172]; [@B184]). There are highly significant, positive correlations between ChAT and ACL activities in cytosolic and synaptosomal fractions isolated from brain regions of variable density of cholinergic innervation ([@B173], [@B176]). Activities of ACL in non-cholinergic neurons, calculated from ACL/ChAT correlation plots, were found to be equal to 2--4 nmol/min/mg protein, respectively. On the other hand, the ACL activity in cholinergic neurons, calculated from regional and cholinergic lesions studies, was in the range of 40 nmol/min/mg protein ([@B176], [@B172]; [@B184]). These calculations remain in accord with immunohistochemical studies demonstrating a strong co-expression of ACL with ChAT and VAChT-expressing neurons in mice hippocampus, fascial nucleus and medulla oblongata ([@B6]). The tight functional links of ACL with cholinergic metabolism were demonstrated by its ability to bind ataxia-related protein forming BNIP-H-ACL-ChAT complex leading to enhanced ACh release ([@B159]). In the newborn rat brain, activity of ACL in all regions was comparably high, serving as a provider of acetyl units for structural lipid synthesis during myelinisation ([@B161]; [@B174]; [@B35]). In the course of brain development ACL activity remained high in all cortical regions, in which ChAT/ACh increased due to maturation of cholinergic neurons.

On the other hand, ACL activity in the cerebellum, devoid of cholinergic elements, decreased several fold in parallel with a maturation-dependent decrease of fatty acid synthesis due to termination of myelin and plasma membrane proteo-lipid structures formation ([@B161]; [@B174]; [@B176]; [@B35]). In addition, large non-cholinergic synaptosomes isolated from the brain cortex and cerebellum contained 4 -- 5 times lower ACL activities than small cortical synaptosomes containing significant fraction of cholinergic elements ([@B80]; [@B172]). Cultured S20 or SN56 neuronal cells expressing mature cholinergic phenotype were found to contain higher activities of ACL than non-cholinergic neuronal and micro or astroglial cells ([@B172]; [@B73]). Such cholino-tropic developmental patterns of ACL would be compatible with the demand of maturing cholinergic neurons for optimal provision of acetyl-CoA for age-dependent elevations of ACh synthesis ([@B174]). Such a claim is supported by studies showing significant 30% decreases of ACL and no changes in other enzymes of acetyl-CoA metabolism activities in hippocampal synaptosomes isolated from septum electro-lesioned rat brain ([@B176]). Similar alterations of ACL were observed in the IgG192 saporin (cholinergic immunotoxin) lesioned brain cortex ([@B184]). These changes remained in accord with 70--80% decays of ChAT activities and ACh synthesis indicating loss of cholinergic neurons ([@B176]; [@B184]). Rat hippocampal synaptosomes contain about 6% subfraction of cholinergic terminals ([@B80]). Therefore, one might estimate, that ACL activities in cholinergic terminals are 10--15 times higher than in non-cholinergic ones ([@B161]; [@B176]).

Thiamine deficiency (TD) in rats caused inhibition of metabolic flux of pyruvate through PDHC, reductions of ACL-dependent fractions of cytoplasmic acetyl-CoA, and quantal ACh release from their brain nerve terminals ([@B65]). When taken together, these data indicate that ACL is preferentially expressed in cholinergic neurons, where it plays a crucial role in adequate provision of acetyl-CoA to the site of ACh synthesis ([@B46]; [@B176], [@B178], [@B166]; [@B188]; [@B6]).

ATP-citrate lyase may form multiple discrete subdomains executing different metabolic functions in the cells. ACL forms BNIP-ACL-ChAT complex facilitating direct provision of acetyl-CoA to the site of ACh synthesis ([@B159]). ACL also constitutes extramitochondrial sub-fractions bound with microsomes and nuclear-chromatin ([@B87]; [@B209]). As such, ACL could form microdomains providing acetyl-CoA directly to acetyl-CoA transporter (AT-1) located in ER membranes ([@B56]; [@B130]). In the nucleus, ACL-derived acetyl-CoA could modulate gene expression through alterations in histone acetylations ([@B77]; [@B103]). Adipocyte studies have revealed that ACL, through cytoplasmic acetyl-CoA synthesis, may suppress expression of ACS. In *ACLYgen* knock-out cells, deficits of glucose derived acetyl-CoA could be partially alleviated by upregulation of ACS2 ([@B209]). In such conditions acetate production by brain mitochondria exceeded that of citrate. This could increase the rate of metabolic flux through upregulated ACS2 ([@B91]; [@B209]). In fact early data revealed that whole brain mitochondria incubated without oxaloacetate/malate produced several times greater amounts of acetate than those of citrate ([@B91]).

### Acetyl-l-Carnitine and Direct Acetyl-CoA Transporting Pathways and Cholinergic Metabolism

Acetyl-l-carnitine is another metabolite involved in indirect transfer of acetyl-CoA from mitochondria to the cytoplasm through membrane-bound carnitine acetyl-transferases ([@B140]; [@B165]). This pathway seems to be independent of other ones described above, introducing some surplus of acetyl-CoA to the cytoplasmic compartment. Thanks to such a mode of action, acetyl-l-carnitine might exert neuroprotective effects and alleviate ACh deficits under different neurotoxic conditions, suppressing acetyl-CoA synthesis ([@B140]; [@B150]; [@B165]).

Chronic, oral application of acetyl-l-carnitine to patients in early stages of AD improved their cognitive functions and increased brain energy phosphate levels against the placebo treated group ([@B129]). In cultured cholinergic neuronal cells, acetyl-l-carnitine partially overcame the detrimental effects of neurotoxic agents through a reduction of acetyl-CoA deficits ([@B165]).

In depolarized cultured cholinergic SN56 cells and brain nerve terminals, the acetyl-CoA could be also transported out of mitochondria directly through Ca-activated, verapamil-sensitive, high permeability anion channels (PTP) ([@B9]; [@B167], [@B165]). The mechanism of direct acetyl-CoA output was also found to exist in whole brain mitochondria derived mainly form glial cells (**Figure [1A](#F1){ref-type="fig"}**) ([@B138]; [@B167]). Analysis of our past reports revealed the existence of direct relationships between cytoplasmic and mitochondrial acetyl-CoA levels in SN56 cholinergic neuronal cells (**Figure [1D](#F1){ref-type="fig"}**). The use of different cytotoxic and cytoprotective agents revealed the existence of two - Ca--dependent and Ca-independent mechanisms of acetyl-CoA synthesis and distribution between mitochondrial and cytoplasmic compartments in the neurons (**Figure [1D](#F1){ref-type="fig"}**).

These diverse acetyl-CoA transporting pathways seem to be particularly important for depolarized cholinergic neurons. In such a functional state, cholinergic nerve terminals release quanta of ACh. This requires instant reconstitution of the ACh pool in presynaptic cholinergic terminals for continuation of neurotransmitter function. It has been shown that nerve terminals are capable of assuring an adequate provision of acetyl-CoA, and maintaining stable levels of ACh and transmission rate, even during prolonged excessive activation ([@B12]; [@B190]; [@B178]). On the other hand, decreases in cytoplasmic acetyl-CoA caused by diverse neurotoxic signals resulted in proportional suppressions of ACh content and the rate of its release from depolarized brain synaptosomes and cultured cholinergic neuronal cells (**Figure [1F](#F1){ref-type="fig"}**) ([@B177], [@B164], [@B166]).

Acetyl-CoA Levels in the Brain
==============================

Acetyl-CoA concentrations in brain compartments are usually much lower than the Km values for several acetyl-CoA utilizing enzymes (**Tables [1](#T1){ref-type="table"}, [2](#T2){ref-type="table"}**). In such conditions, alterations in acetyl-CoA level may play a role of the primary factor regulating *in situ* activities of acetyl-CoA utilizing enzymes and thereby flow rates through respective metabolic pathways ([@B190]; [@B166], [@B171]; [@B130]). The analysis of acetyl-CoA determinations performed within a 50-year time span in different preparations of the brain using diverse methodologies demonstrates their strikingly good intrinsic comparability (**Table [2](#T2){ref-type="table"}**). In general, acetyl-CoA concentration in whole brain tissue was reported to be below 0.01 mmol/L, with intramitochondrial levels being somewhat higher than those in the cytoplasmic compartment (**Table [2](#T2){ref-type="table"}**). Some data presenting several times higher acetyl-CoA concentrations in the brain may correspond to the sum of CoA-SH + acetyl-CoA levels (**Table [2](#T2){ref-type="table"}**) ([@B212]). There are also indications that acetyl-CoA levels in neurons may be higher than in astroglial and lower than in microglial cells (**Table [2](#T2){ref-type="table"}**) ([@B73]; [@B213]).

The heterogeneity of neuronal groups in the brain, as well as diversity of neurotransmitter systems and functions may imply differences in acetyl-CoA concentrations and pathways of its inter-compartmental redistribution (**Figure [2](#F2){ref-type="fig"}**) ([@B157]; [@B168], [@B178], [@B171]; [@B138]; [@B45]). Such a thesis is justified by studies of cholinergic neurons with high expression of the cholinergic phenotype, which displayed lower concentrations of acetyl-CoA than those with low expression of this phenotype, or non-cholinergic ones ([@B10]; [@B175], [@B166]; [@B213]). Moreover, cholinergic differentiation -- despite a decrease of whole cell acetyl-CoA -- was linked with its redistribution to the cytoplasmic compartment, resulting in a substrate-dependent increase in rate of ChAT reaction (**Figure [2](#F2){ref-type="fig"}**). It would also be compatible with the increased demand for acetyl groups for ACh synthesis in mature cholinergic neurons ([@B105]; [@B10]; [@B175], [@B166]). One may suspect that neurons of different neurotransmitter systems might contain variable profiles of intraneuronal compartmentation acetyl-CoA. Therefore, estimations of acetyl-CoA level in whole brain tissue may not adequately reflect the distribution of this metabolite between subcellular compartments in specific cell groups (**Table [2](#T2){ref-type="table"}**) ([@B138]; [@B178], [@B166]; [@B130]; [@B153]).

![Effects of cholinergic differentiation with dibutyryl-cAMP/RA (DC) and/or with nerve growth factor (NGF) and amyloid-β (Aβ) on PDHC and ChAT activities, acetyl-CoA distribution, acetylcholine content and loss of viability of **(A,B)** cholinergic neuroblastoma SN56 with surface TrkA(+) and p75^NTR^(+) NGF receptors; **(C,D)** SN56 with TrkA(--) and p75^NTR^(+) NGF receptors. Absolute values of enzyme activities and metabolite levels corresponding to 0 ordinate are given in **Table [3](#T3){ref-type="table"}**.](fncel-12-00169-g002){#F2}

Metabolic Regulations Through Acetyl-CoA Levels Alterations
-----------------------------------------------------------

### Mitochondrial Acetyl-CoA, Energy Production, and Neuronal Viability

The PDHC plays a principal role in adequate provision and maintenance of the proper level of acetyl-CoA in mitochondrial compartment of neurons, platelets and, presumably, in other cell types. The enzyme is sensitive to several neurotoxic signals both under *in vivo* and *in vitro* experimental models of neurodegeneration. Inhibitors and activators of PDHC caused decreases and increases of acetyl-CoA in mitochondrial compartment of brain nerve terminals and cultured cholinergic neuroblastoma cells, respectively (**Figures [1A,B](#F1){ref-type="fig"}**) ([@B166], [@B171]). Non-toxic, low nmolar concentrations of Aβ inhibited PDHC activity *in situ* in rat hippocampal cell culture through its hyper-phosphorylation which was activated o tau protein kinase I and glycogen synthase kinase 3 ([@B58], [@B57]). Similar conditions may occur in the brains of AD 2576Tg and 3xTg mice, in which sub micromolar Aβ accumulation was accompanied by mental impairment, suppression of pyruvate uptake, a drop of acetyl-CoA content and ACh synthesis in nerve terminals at non-altered PDHC and ChAT activities ([@B205]; [@B8]). These findings are in accord with observations of different Tg models of AD demonstrating co-existence of diverse synaptosomal mitochondrial dysfunctions as well as cholinergic and/or behavioral deficits with amyloidosis ([@B126]; [@B136]; [@B199]; [@B197]). On the other hand, no alterations of PDHC and KDHC activities, but an increase of pyruvate uptake, was observed in whole brain mitochondria originating predominately from non-neuronal cells ([@B8]). For the above reasons, the observations made on whole brain tissue may overlook the unique alteration of pyruvate metabolism in individual cellular compartments of the brain.

There is general agreement that the increase of Zn in postsynaptic neurons of gluzinergic synapses is one of earliest events of neurodegeneration ([@B149]; [@B49]). This cation, in combination with Ca shifts, is considered to be a critical factor in excitotoxic cascade yielding excessive production of NOS and ROS resulting in inhibition of PDHC and diverse enzymes of energy metabolism ([@B142], [@B141]; [@B49]; [@B213]). Common cytotoxic signals such as hypoxia/ischemia and neuroinflammation may inhibit PDHC activity both in astroglial and neuronal cells through activation of PDH kinase. Aging was found to activate c-JUN-N-terminal kinase, which inhibits PDHC activity through phosphorylation of E1α subunit leading to a decrease of ATP levels in aged brains ([@B211]). The suppression of oxidative decarboxylation of pyruvate may result in hyperlactatemia, lactate was found to act as an intercellular signaling/messenger molecule modulating neuronal plasticity, neuron glia interactions and inflammatory pain ([@B53]; [@B67], [@B66]). There is also a possibility that pyruvate may itself serve not only as an energy substrate but also as a neuroprotective agent. Chronic intraperitoneal application of large doses of pyruvate to 3xTg AD mice improved memory deficits by non-energy linked reductions of oxidative stress, hyperexcitability, and maintenance of Ca/Zn homeostasis without affecting Aβ/tau pathology ([@B62]). Activation of brain PDHC by dichloroacetate (DCA) alleviated neurological complications and improved the survival of rats after cardiac arrest ([@B196]). There is also evidence that pyruvate derived acetyl-CoA is a direct modulator of neuronal viability. The rate of neuronal SN56 cell injury by multiple neurotoxic signals displayed strong direct correlation both with rates of pyruvate utilization and acetyl-CoA levels in neuronal mitochondria (**Figures [1A,B](#F1){ref-type="fig"}**) ([@B166], [@B171]). The exogenous high energy compounds -- ATP, phosphocreatine as well as acetyl-CoA -- promoted physiological processing of APP and boosted survival in the cultured human SH-SY5Y neuronal cell ([@B146]).

Therefore, one may assume that decreases in uptake F^18^-deoxyglucose, binding of cholinergic ligands, and a drop of NAA level in MRI/PET images of AD patient's brains may be directly linked with acetyl-CoA deficits (**Figure [1](#F1){ref-type="fig"}**) ([@B210]; [@B81]; [@B147]). The regional pattern of these changes in individual AD patients matched well with specific clinical symptoms of their cognitive deficits ([@B109]; [@B63]). These findings are compatible with postmortem studies of AD brains, revealing decreases of PDHC and TCA enzymes as well as cholinergic markers including ChAT, high affinity choline uptake (HACU), M~2~ muscarinic autoreceptors, and VAChT ([@B181]; [@B118]; [@B18]; [@B110]; [@B131]; [@B63]). These deficits could be also caused by direct, reversible inhibition of ChAT by Aβ oligomers, yielding cholinergic dysfunction without apparent structural impairment of neuronal terminals ([@B58], [@B57], [@B116]; [@B8]). However, some patients develop clinical symptoms of AD without accumulation of Aβ ([@B63]). It is also apparent that ca. 80% of elderly subjects display AD-type amyloid deposits, but relatively few of them suffer from AD ([@B37]; [@B147]). These inconsistencies may be linked with the occurrence of different ApoE phenotypes in the AD population. Thus, 99% of AD apoE4^+^ patients were also florbetapir positive, whereas in the AD apoE4- subgroup only 60% were florbetapir positive ([@B63]). There is also a possibility that acetyl-CoA and energy deficits may appear much earlier and trigger the onset of different cholinergic encephalopathies, including AD ([@B166]; [@B63]). However, there is no data whether acetyl-CoA alterations might be involved in phenotypic diversity of AD.

The KDHC is an enzymatic complex of relatively low activity, thereby being a rate limiting step for the TCA cycle. Its inhibition seen in AD, TD, hepatic encephalopathy, and other brain pathologies has been identified as a primary factor responsible for energy deficits in neurodegenerating brains, being extensively reviewed elsewhere ([@B44]; [@B20]).

### Mitochondrial Acetyl-CoA and NAA Metabolism

In each type of brain cells, a major fraction of acetyl-CoA generated in mitochondria in PDHC reaction is utilized in the TCA cycle covering 98% of the energy demand. The alterations in rate of *in situ* pyruvate oxidation may bring about respective changes in levels of acetyl-CoA in the neuronal mitochondrial compartment. Inhibition of PDHC decreased availability of this substrate for the TCA cycle, yielding a decrease of ATP levels (**Figures [1A,B](#F1){ref-type="fig"}**) ([@B213]). Alterations in cytoplasmic acetyl-CoA levels correlated with its level and outward transport from the mitochondrial compartment as well as with viability of cholinergic neuronal cells ([@B166]; [@B213]) (**Figure [1D](#F1){ref-type="fig"}**). In addition, 1--3% fraction of neuronal mitochondrial pool of this metabolite pool is converted intramitochondrially by aspartate *N*-acetyltransferase (AAT, EC 2.3.1.17) to NAA ([@B5]; [@B213]). Therefore, neurons contain 98.5% of whole brain NAA. One may assume that at whole brain concentration of this amino acid, being in the range of 10 mmol/L, its intraneuronal level is likely to be several times higher ([@B5]).

*N-*acetyl-l-aspartate is transferred from axons through axo-glial contact zones to oligodendrocytes and hydrolyzed to acetate by cytoplasmic *N*-acetyl aspartate aminohydrolase (EC 3.5.1.15) ([@B5]; [@B107]). This enzyme plays a significant role in myelination during brain ontogenesis, providing acetyl units for oligodendroglial energy production and fatty acid synthesis ([@B39]). Mutations in the aspartate aminohydrolase gene result in failure of myelin formation, manifested phenotypically as congenital pediatric leukodystrophy -- Canavan's disease ([@B107]; [@B39]). Postmortem studies of multiple sclerosis brains revealed decreased levels of NAA and acetate in gray matter from parietal and motor cortex. They suggest that mitochondrial dysfunction and reduced levels of acetyl-CoA might yield deficits of NAA in neurons, which in turn would decrease its transport to oligodendrocytes. That could result in insufficient availability of acetate compromising energy production and myelin formation in these cells ([@B86]; [@B171]).

Aspartate *N*-acetyltransferase, the enzyme synthesizing NAA is located exclusively in neuronal mitochondria ([@B5]). Its Km values for acetyl-CoA and l-aspartate are equal to 58 and 580 μmol/L, whereas concentrations of these metabolites in the brain are estimated to be 7.5--14.0 and ca. 3500 μmol/L, respectively (**Tables [1](#T1){ref-type="table"}, [2](#T2){ref-type="table"}**; [@B128]; [@B92]; [@B117]). In such conditions, *in situ* metabolic flux through AAT reaction is estimated to be equal to ca. 16% of its maximal activity ([@B213]). Therefore, *in vivo*, at saturating levels of l-aspartate, the yield of AAT reaction may depend exclusively on acetyl-CoA concentration in the neuronal mitochondrial compartment. For instance, exposition of cholinergic SN56 neuronal cells to low-toxic Zn concentration, affected neither PDHC nor AAT levels/activities, but brought about similar ca. 50% decreases of pyruvate oxidation, acetyl-CoA, and NAA levels (**Figures [1B,C](#F1){ref-type="fig"}**). In these conditions, decreases in NAA levels strongly correlated with reductions of acetyl-CoA levels in whole cells and in mitochondrial compartment (*p* \< 0.001) (**Figure [1C](#F1){ref-type="fig"}**) ([@B213]). This would be a first direct evidence for the thesis that alterations in NAA level in MRI imaging, seen in the gray matter of a neurodegenerating brain, may reflect changes in availability of acetyl-CoA in the neuronal compartment (**Figure [1C](#F1){ref-type="fig"}**) ([@B5]; [@B107]; [@B166], [@B171]; [@B147]).

### Cytoplasmic Acetyl-CoA and ACh Metabolism

The functional and structural loss of cholinergic transmitter functions in the basal forebrain is a key feature of AD pathology and also includes acetyl-CoA deficits ([@B41]; [@B114]; [@B8]; [@B125]). The level of acetyl-CoA in the cytoplasmic compartment of neuronal cells is a result of the rates of its synthesis and utilization in mitochondria and the rate of its efflux to the cytoplasm through different direct (Ca-dependent) and indirect (metabolic) mechanisms ([@B190]; [@B178], [@B166]). Compounds altering acetyl-CoA synthesis in mitochondria and increasing their membrane permeability tend to yield higher levels of cytoplasmic acetyl-CoA (**Figure [1D](#F1){ref-type="fig"}**, green plot) than those not changing or inhibiting membrane permeability (**Figure [1D](#F1){ref-type="fig"}**, blue plot). The comparisons of Km values for acetyl-CoA against different enzymes utilizing this substrate indicate that the rates of metabolic fluxes through these metabolic steps *in situ* may be several times lower than the activities of respective enzymes estimated at saturating or suboptimal substrates concentrations (**Tables [1](#T1){ref-type="table"}, [2](#T2){ref-type="table"}**).

The ChAT is expressed exclusively in brain cholinergic neurons, being a biomarker of their structural integrity and capacity to synthesize neurotransmitter ACh from choline and acetyl-CoA. Acetyl-CoA Km values for brain ChAT, reported in the literature, are in the range of 35--200 μmol/L (**Table [2](#T2){ref-type="table"}**) and those of choline vary from 400 to 1500 μmol/L ([@B143]; [@B145]; [@B76]). On the other hand, averaged concentration of free choline in the brain was assessed to be ca. 60 μmol/L ([@B151]; [@B17]; [@B188], [@B189]; [@B72]), and that of acetyl-CoA to be close to 7 μmol/L, respectively (**Table [2](#T2){ref-type="table"}**). Kinetic studies on ChAT preparations purified from rat brain revealed that in medium containing high phosphate -- low chloride concentrations, characteristic for intracellular compartment, the Km's for acetyl-CoA and choline were equal to about 40 and 1000 μmol/L, respectively (**Table [1](#T1){ref-type="table"}**) ([@B143]; [@B145]). They are several times higher than intracellular levels of these substrates (**Tables [1](#T1){ref-type="table"}, [2](#T2){ref-type="table"}**). Considering such concentrations and kinetic constants for those metabolites, one may calculate that metabolic flux through ChAT in cholinergic neurons *in situ* is likely be equal to ca. 0.8% of maximal velocity of the enzyme, assessed at saturating concentrations of substrates ([@B176]; [@B189]; [@B76]). Such an approximation is compatible with rates of ACh synthesis in brain synaptosomes utilizing glucose or pyruvate, corresponding to 0.75--1.24% of their maximal ChAT activity ([@B174]; [@B168]; [@B9]; [@B11], [@B8]; [@B184]).

The murine cholinergic SN56 neuroblastoma cells of septal origin, contain somewhat higher intracellular concentrations of acetyl-CoA and choline, of about 10 and 250 μmol/L, respectively (**Table [2](#T2){ref-type="table"}**) ([@B83]). Based on the same equation, the calculated ChAT velocity in SN56 cells *in situ* should be equal to ca. 4% of its maximal rate ([@B64]; [@B175], [@B164]). Accordingly, K/Ca-induced rates of ACh synthesis in differentiated SN56 were found to vary from 1.9 to 3.5% of maximal ChAT activities, being close to its calculated *in situ* activities ([@B64]; [@B175], [@B164]; [@B8]). In such conditions the availability of acetyl-CoA in cytoplasmic compartment may be a primary factor limiting rate of ACh synthesis through concentration-dependent regulation ChAT activity (**Figures [1E,F](#F1){ref-type="fig"}, [2](#F2){ref-type="fig"}**) ([@B188], [@B189]; [@B166], [@B171]). It is also certain that pyruvate, through PDHC step, is a main source of acetyl moieties for ACh synthesis ([@B85]; [@B46]; [@B157]; [@B9]). In fact, significant alterations in intraneuronal acetyl-CoA distribution were found to take place both in physiologic and neurotoxic conditions, differentially affecting mitochondrial synthesis, transport, and its utilization in cytoplasmic compartments of cultured neuronal cells and brain synaptosomes (**Figure [1](#F1){ref-type="fig"}**) ([@B166], [@B171]). In maturing cholinergic neurons, increases of cytoplasmic level of acetyl-CoA may combine with elevation of ChAT expression, yielding a non-proportionally higher increase in the rate of ACh synthesis. For instance, cAMP/RA-induced differentiation of cholinergic SN56 cells brought a ca. 110 and 40% increases of ChAT activity and cytoplasmic acetyl-CoA level, but a 290% activation of ACh synthesis, respectively ([@B7]). This suggests the existence of synergistic, positive cooperative interactions of independent elevations of ChAT activity and acetyl-CoA levels in the stimulation of neurotransmission in maturing cholinergic neurons ([@B7]). Studies on developing rat brains revealed that adequate provision of acetyl-CoA to cytoplasmic compartment in maturing cholinergic neurons may be supported by the increase of ACL activity ([@B161]; [@B176]).

Primary and secondary thiamine deficits disturb cholinergic transmission in the brain, impairing the cognitive and motor functions in affected individuals ([@B43]; [@B20]; [@B65]). Thiamine-deficient rats displayed inhibition of ACh synthesis and release, despite the unchanged activities of ChAT -- indicating the preservation of cholinergic neurons integrity in these conditions. Thus, TD-evoked inhibition of ACh metabolism resulted exclusively from *in situ* inhibition of pyruvate oxidation by PDHC, yielding decreased availability of acetyl-CoA in the mitochondria and its secondary deficits in the ACh synthesizing compartment. (**Figures [1A,E](#F1){ref-type="fig"},[F](#F1){ref-type="fig"}**). In these conditions, the rate of ACL-dependent fraction of ACh synthesis/release fell from 0.52 to 0.26% of maximal ChAT activity ([@B65]).

In addition, in cultured SN56 cholinergic cells acute Zn overload or amprolium-thiamine depletion caused inhibition of PDHC activity and proportional suppressions of cytoplasmic acetyl-CoA level and ACh synthesis without altering ChAT activity (**Figures [1A,E,F](#F1){ref-type="fig"}**) ([@B141]; [@B13]). In the early stages of Aβ encephalopathies, inhibition of cholinergic transmission may be brought about exclusively by deficits of acetyl-CoA within structurally preserved neurons (**Figures [1E,F](#F1){ref-type="fig"}**) ([@B58], [@B57]; [@B33]; [@B8]). Such reversible alterations may precede late structural losses of cholinergic neurons ([@B187]; [@B166], [@B171]). In fact, persistent exposition of differentiated SN56 cells to Zn or NO excess, simulating chronic excitotoxic conditions, brought about their morphologic deterioration and death. Neurons surviving such treatments displayed irreversible loss of both PDHC and ChAT, yielding deficits of mitochondrial and cytoplasmic acetyl-CoA and ACh metabolism ([@B142]; [@B73]; [@B213]). In latter experiments, suppressions of acetyl-CoA/ACh metabolism were caused by combination of functional and mal-adaptative structural alterations ([@B166], [@B171]).

One of the consequences of acetyl-CoA deficits in neuronal cytoplasm of AD brains may be decreased activity of cytoplasmic SphK1 ([@B25]; [@B8]). This enzyme, besides being protein kinase, also displays cyclooxygenase 2 transacetylase activity with Km for acetyl-CoA equal to 58.2 μM. This value is several times higher than neuronal levels of this metabolite (**Tables [1](#T1){ref-type="table"}, [2](#T2){ref-type="table"}**) ([@B84]). Acetylation of COX2 stimulates secretion of specialized proresolving mediators, which increase phagocytosis by microglia different aberrant proteins, including Aβ. There is an inverse correlation between SphK1 activity and Aβ levels in the brains of AD patients ([@B25]). Hence, shortages of acetyl-CoA in cytoplasmic compartment might facilitate Aβ formation, due to decreased acetylating activity of SphK1 ([@B84]). Accumulating Aβ may further aggravate acetyl-CoA deficits, directly inhibiting PDHC activity (**Figures [2A,C](#F2){ref-type="fig"}**) ([@B58], [@B57]).

### Nerve Growth Factor and Neuronal Acetyl-CoA

Nerve growth factor (NGF) is a cholinotrophic cytokine that regulates the maturation, development, and maintenance of basal cholinergic neurons through retrograde signals mediated by high affinity specific TrkA and low affinity, non-specific p75^NTR^ receptors ([@B162]; [@B26]; [@B175]; [@B15]; [@B61]; [@B82]). Regional distribution of NGF protein and its mRNA correlate with density of cholinergic innervation ([@B75]). Intracerebroventricular injections of NGF to neonatal rats increased in a dose-dependent manner ChAT and HACU activities in all groups of basal forebrain cholinergic neurons ([@B47]; [@B106]; [@B2]). Similar cholinotrophic effects of NGF application were observed in adult animals ([@B201]). Positive cholinotrophic effects of NGF were also observed *in vitro* in cultured hippocampal slices, primary cultures of septal and striatal neurons, as well as in PC12 and SN56 cholinergic cell lines. In each case NGF elevated expression of cholinergic phenotype bio-markers including; fractional content of ChAT positive cells, ChAT, HACU, VAChT levels/activities, as well as ACh contents and rates of its release ([@B99]; [@B40]; [@B162]; [@B175]; [@B93]; [@B82]; [@B108]). These adaptative positive cholinotrophic effects of NGF/BDNF are executed through TrkA/TrkB - CREB dependent signaling pathway yielding increased expression of the cholinergic locus and activation of Ca-accumulation/mobilization systems ([@B68]; [@B38]; [@B26]). Similar differentiating effects are attained with diverse differentiation protocols acting through the mechanism of CREB activation ([@B162]; [@B30]). Impairment of TrkA/NGF signaling was involved in pathomechanism of early presynaptic dysfunction of cholinergic neurons ([@B82]). It was found to drive Aβ accumulation in cholinergic neurons ([@B185]). NGF administration prevented excitotoxic atrophy of cholinergic basal forebrain neurons ([@B27]). Treatment of neural stem cells *in vitro* with NGF stimulated their transformation toward fully functional cholinergic neuron-like cells which after transplantation into APP/PS1 transgenic mice corrected their cholinergic and behavioral deficits ([@B50]).

The p75^NTR^ receptor is a non-specific receptor shared by all four neurotrophins ([@B26]). Its heterodimeric complex with TrkA increased affinity to NGF and augmented Ca influx, promoting maturation of basal cholinergic neurons (**Table [3](#T3){ref-type="table"}**) ([@B68]; [@B95]; [@B207]). On the other hand, occupancy of homodimeric form of p75^NTR^ by NGF triggered ceramide-programed cell death ([@B23]; [@B16]; [@B95]). The excess of p75^NTR^ signaling may aggravate cognitive deficits through phenotypic suppression of cholinergic neurons ([@B23]; [@B95]). *In vivo* knock down of p75^NTR^ increased ChAT activity in aging rats ([@B4]). The reduction of p75^NTR^ expression ameliorated cognitive and cholinergic deficits in Tg2576 mice ([@B111]).

###### 

Basal parameters of acetyl-CoA and ACh metabolism in TrkA(-) and TrkA(+) cholinergic SN56 neuronal cells.

  Parameter                                           TrkA(+p75^NTR^(+)   TrkA(-) p75^NTR^(+)
  --------------------------------------------------- ------------------- ---------------------
  PDHC activity *(nmol/min/mg protein)*               7.25 ± 0.31         7.60 ± 0.23
  Mitochondrial acetyl-CoA *(pmol/mg protein)*        15.9 ± 2.1          14.2 ± 0.4
  Cytoplasmic acetyl-CoA *(pmol/mg protein)*          20.1 ± 3.9          32.4 ± 3.6
  Choline acetyltransferase *(nmol/min/mg protein)*   0.178 ± 0.017       0.188 ± 0.011
  Acetylcholine level *(pmol/mg protein)*             149 ± 5.0           169 ± 6.0
  Non-viable cell fraction *(%)*                      5.5 ± 0.5           6.3 ± 0.4

Data for recalculations were taken from:
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,
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.

Differentiation of both TrkA(+)p75^NTR^(+) and TrkA(-)p75^NTR^(+) septal cholinergic SN56 neurons with cAMP/RA increased the density of p75^NTR^ receptors, apparently promoting their homo-dimerization ([@B175], [@B164]; [@B4]). Such treatment also caused morphologic maturation and elevations of ChAT activity and ACh content in both TrkA (+)p75^NTR^ (+) and TrkA (-)p75^NTR^ (+) cells (**Table [3](#T3){ref-type="table"}**). This was accompanied by a shift of acetyl-CoA from the mitochondria to their cytoplasm. The increased acetyl-CoA level in the cytoplasm was compatible with increased demand for acetyl units by activated ACh synthesis (**Table [3](#T3){ref-type="table"}**) ([@B175], [@B165]). NGF application to non-differentiated cells increased ChAT/ACh only in cells with TrkA(+) but not with TrkA(-)phenotype. Moreover, NGF added either to cAMP/RA differentiated TrkA(+) and TrkA (-)cells caused parallel suppression of cytoplasmic acetyl-CoA levels and ChAT activities, as well as an increase of non-viable cell fractions (**Figures [2B,D](#F2){ref-type="fig"}**). It also aggravated the cytotoxic effects of Aβ or NO excess mediated by the increased density of p75^NTR^ in DC (**Figure [2](#F2){ref-type="fig"}**) ([@B164]). These negative alterations were alleviated by the simultaneous addition of anti-p75^NTR^ antibodies ([@B175], [@B165]). These data indicate that both the cytoprotective/cholino-trophic and cholino-suppressive effects of NGF may be at least in part mediated through alterations of acetyl-CoA levels in mitochondrial and cytoplasmic compartments of cholinergic neurons, respectively.

### Endoplasmic Reticulum and Nuclear Acetylations

Extramitochondrial acetyl-CoA directly affects acetylation levels of several proteins located in separate cytoplasmic, ER, and nuclear compartments. In peripheral tissues, starvation induces the depletion of cytoplasmic acetyl-CoA and protein deacetylation, being a principal signal triggering autophagy ([@B97]). On the other hand, the replenishment of acetyl-CoA by DCA or lipoic acid inhibited autophagy through increased protein acetylations. The acetyltransferase EP300 was required for autophagy suppression by high concentrations of acetyl-CoA ([@B97]). Also, in the brain maintenance of a proper level of protein acetylation is achieved by diverse lysine acetyltransferases, including CREB-binding protein and F1A-associated protein p300. The latter seem to be crucial for normal neurodevelopment and cognitive processes ([@B191]). Both hypoacetylation and hyperacetylation may bring about a similar spectrum of dysfunctions and/or neurodegenerative disorders ([@B191]).

A small, yet unknown fraction of cytoplasmic acetyl-Co-A has to be sub-distributed into ER/Golgi compartments to supply acetyl units for acetylation reactions of lysine residues in hundreds of structural proteins in order to regulate their turnover and activity ([@B77]; [@B122]; [@B25]). There is no acetyl-CoA synthesizing enzymes in ER lumen. However, ACS or ACL binding to ER may facilitate the provision of acetyl-CoA into their proximity ([@B87]; [@B103]). Such fine compartmentalization of these enzymes may assure the efficient transport of acetyl-CoA into ER by the specific membrane transporter (AT-1), a member of multiple transporters of the SLC33 family ([@B70]; [@B56]). It would maintain acetyl-CoA on the level sufficient for activation of transient acetylations of lysine groups of different proteins in the ER lumen by specific lysine protein acetyltransferases ([@B31]). They would include, among others, acetylations of β-amyloid precursor protein cleaving enzyme 1 (BACE 1), low density lipoproteins receptor (LDLR) or amyloid precursor protein (APP), and tubulin ([@B77]; [@B70]; [@B204]). Nuclear transacetylases were found to carry regulatory acetylations of histones and transcription factors modifying neuronal phenotype, plasticity, and memory/cognitive functions ([@B77]; [@B103]).

The true level of acetyl-CoA in ER remains unknown, nevertheless it might be close or somewhat higher than that in the cytoplasmic compartment (**Table [2](#T2){ref-type="table"}**). The Km values for acetyl-CoA for AT-1 transporter in ER membranes are in the range of 14 μmol/L, being higher than cytoplasmic concentrations of this metabolite (**Tables [1](#T1){ref-type="table"}, [2](#T2){ref-type="table"}**; [@B31]; [@B70]). Therefore, the rate of acetyl-CoA influx into the ER compartment may be appropriately altered both by increases and decreases of cytoplasmic levels of this metabolite taking place during neuronal maturation or excitotoxic injury, respectively (**Figure [1](#F1){ref-type="fig"}**) ([@B162]; [@B175], [@B166]; [@B31]; [@B122]).

On the other hand, the nuclear membrane seems to be fully permeable for acetyl-CoA. In addition, its provision directly to acetylation sites is thought to be conducted by nuclear subfractions of ACL and ACS2 ([@B200]; [@B103]). The presence of nuclear PDHC was also documented by [@B155]. Such specific compartmentation of several acetyl-CoA producing enzymes drives preferential utilization of this metabolite for acetylations of nuclear proteins by numerous HAT ([@B77]; [@B36]; [@B155]). This process would be facilitated by the fact that affinities of nuclear HATs to acetyl-CoA were found to be very high, with Km values being in range of 0.3--4.8 μmol/L (**Table [1](#T1){ref-type="table"}**) ([@B3]; [@B42]; [@B198]). Therefore, neuronal-cytoplasmic acetyl-CoA concentrations of 8--13 μmol/L may assure sub-maximal rates of metabolic fluxes through nuclear acetyltransferases (**Tables [1](#T1){ref-type="table"}, [2](#T2){ref-type="table"}**). Consequently, the degree of nuclear histones acetylations might be regulated rather by amount/ratios of HATs and histone deacetylases than by acetyl-CoA concentration itself.

In fact, remarkable changes in proteins acetylations take place in different pathologic and physiologic conditions. Human brain autopsy revealed that increased acetylation of tau protein in AD and chronic traumatic encephalopathy brains may precede subsequent critical phosphorylation at lysine 280 ([@B90]). On the other hand, deficient import of acetyl-CoA into ER lumen, in haploinsufficient mice carrying point mutation (S113R) in AT-1, was also associated with neurodegeneration, susceptibility to infections and increased risk of cancer ([@B124]). In another work, the same haploinsufficiency of AT-1 alleviated brain degeneration processes in (APP~695/swe~) transgenic AD mice, but not in those with Huntington's disease (HD, R6/2) or ALS (hSOD^G93A^) ([@B123]). This discrepancy may result from the fact that inhibition of ER acetylations improved autophagy-mediated disposal toxic protein in AD. On the other hand, removal of HD and ALS aggregates took place in the cytoplasm and could not be affected by ER acetylations ([@B123]). One of the sources of such discrepancies in these pathologies could be also variable alterations in PDHC activity, which was suppressed in AD and not altered in HD ([@B18]; [@B113]). That might also generate differences in acetyl-CoA availability in mitochondria yielding respective down-stream changes in extramitochondrial distribution of this metabolite ([@B166], [@B171]; [@B8]; [@B123]). Inhibitors of histone deacetylase could exert an indirect cytoprotective effect alleviating dysfunction of PDHC, suppressing its kinases ([@B112]). Tubastatin A, the inhibitor of histone deacetylase 6 alleviated stroke-induced infarction and functional deficits, preventing a decrease in α-tubulin acetylation evoked by occlusion of middle cerebral artery ([@B197]). Inhibition of this enzyme also prevented degeneration of pluripotent stem cells from ALS patients, increasing the level of α-tubulin acetylation and the integrity of ER and axonal transport ([@B51]).

Endogenous repair of neurons in the brain is impeded by chondroitin sulfate proteoglycans or myelin associated proteins, which were found to suppress α-tubulin acetyltransferase, thereby preventing axon regeneration and growth of primary cortical neurons ([@B204]). The reconstitution level of α-tubulin acetyltransferase by lentiviral expression or increase of Rho-associated kinase reversed tubulin acetylation and neuronal growth ([@B204]). The application of icariin, a plant flavonoid, to mice with traumatic brain injury increased the acetylation of histones and prevented loss of ChAT activity and ACh content in the hippocampus ([@B208]). Injection of another deacetylase inhibitor trichostatin A into the hippocampal CA1 area of prenatally stressed rats prevented the development of depressive behavior and reversed the suppression of AMPA glutamate receptors mRNA in the hippocampus ([@B89]). On the other hand, excessive expression of AT1/SLC33A1 in an AT-1 Tg mouse model affected dendritic branching, spine formation, and key metabolic pathways yielding cognitive deficits and autistic-like phenotype ([@B60]).

Conclusion
==========

Pyruvate-derived acetyl-CoA and oxaloacetate are principal energy-precursor substrates feeding the TCA cycle in the brain mitochondria. A relatively small fraction of mitochondrial acetyl-CoA is utilized in a large number of diverse synthetic pathways taking place in different subcellular compartments. In addition, each type of brain neuronal and glial cells apparently possesses their own individual, unique metabolic profile of acetyl-CoA distribution, fitting their specific functions. At least four subcellular structural and functional acetyl-CoA compartments have been identified, which utilize this intermediate for synthesis of a diverse range of acetylated regulatory and signaling compounds. The concentrations of acetyl-CoA in different subcellular compartments are low and may change in a fairly broad range in the course of different physiologic and pathologic conditions. On the other hand, acetyl-CoA metabolizing enzymes display relatively low affinity to this substrate. Therefore, pathophysiologic alterations in intracellular compartmentation of acetyl-CoA may be early primary signals that deeply modify cell viability and function.

In the mitochondrial compartment of neurons, the rate of NAA synthesis by AAT correlates, with acetyl-CoA level, which also directly affects neuronal viability. The output of acetyl-CoA from mitochondrial to extramitochondrial compartments depends on the rate of its synthesis by PDHC and the capacity of transport systems in the mitochondrial membranes. In cholinergic neurons, mitochondrial levels of acetyl-CoA are lower and those in the cytoplasm are higher than in respective compartments of non-cholinergic cells. The high level of acetyl-CoA in mature cholinergic neurons cytoplasm is necessary for the maintenance rate of ACh synthesis adequate to its release. In different pathophysiological conditions, the rates of ACh synthesis and release directly correlated with the levels of acetyl-CoA in the cytoplasmic compartment of the neuron. The NGF-evoked, TrkA/p75^NTR^ dependent maturation of cholinergic neurons and their susceptibility to injury may be mediated by changes in intracellular redistribution of acetyl-CoA. The provision of acetyl-CoA to ER and nuclear sub-compartments may play a key role in the development and maintenance of neuronal cells viability through alteration of the acetylation level of lysine residues of a very large range of regulatory proteins and peptides.

This review illustrates that alterations in concentration and intracellular compartmentalization of acetyl-CoA play a significant role in direct substrate-dependent regulation of multiple acetylation reactions velocities, as well as signaling molecule changing properties of several regulatory peptides and proteins. More research is required to uncover the role of acetyl-CoA in pathomechanisms and potential therapeutic approaches to neurodegenerative diseases.
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βHB

:   β-hydroxybutyrate

AAT

:   aspartate-*N*-acetyltransferase

AcAc

:   acetoacetate

ACh

:   acetylcholine

AD

:   Alzheimer's disease

ALS

:   amyotrophic lateral sclerosis

AT-1

:   acetyl-CoA transporter-1(endplasmic reticulum)

ChAT

:   choline acetyltransferase

ER

:   endoplasmic reticulum

HACU

:   high affinity choline transporter

HAT

:   histone acetyltransferase

HBDH

:   β-hydroxybutyrate dehydrogenase

HC

:   (-)hydroxycitrate

KDHC

:   α -ketoglutarate dehydrogenase complex

NAA

:   *N*-acetyl-[L]{.smallcaps}-aspartate

NGF

:   nerve growth factor

NOS

:   nitrogen oxide reactive species

PDHC

:   pyruvate dehydrogenase complex

RA

:   retinoic acid ROS, reactive oxygen species

SphK1

:   sphingosine kinase 1

TCA

:   tricarboxylic acid cycle

VAChT

:   vesicular acetylcholine transporter
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